Lonza Group stock gains on new US manufacturing investment plan
Published on 09/20/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock (ISIN CH0013841017) is in focus after the Swiss contract manufacturer confirmed plans on September 19, 2026 to build a new factory in Bend, Oregon, expanding its US spray drying capacity for complex drug formulations, according to Nutrition Industry Executive Magazine.
Factory plan in Oregon expands US footprint
The planned Bend, Oregon site will further strengthen Lonza's manufacturing presence in the United States as it targets growing demand for advanced pharmaceutical ingredients, as reported on September 19, 2026 by Nutrition Industry Executive Magazine.
According to Swissinfo in a report dated September 19, 2026, the factory will focus on spray drying technologies used to improve the solubility and stability of complex drug molecules, supporting pharma customers that increasingly outsource these sophisticated processes.
Stock trades below recent highs
On September 19, 2026, Lonza Group shares on SIX Swiss Exchange traded below their 52-week high, indicating that while the Oregon investment is a positive strategic signal, investors are still balancing it against recent earnings trends and guidance; the exact price level and range reflect a market that prices in both growth opportunities and execution risks.
Closing price and investor takeaway
As of September 19, 2026, Lonza Group stock on SIX Swiss Exchange closed below its recent peak in Swiss francs, leaving a measurable gap to the 52-week high that investors will watch as the Bend, Oregon project advances and new capacity comes onstream.
Lonza Group stock key data
- Company: Lonza Group Ltd.
- ISIN: CH0013841017
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Pharmaceuticals and Biotechnology
- Index membership: SMI
